National Prescribing Trends of Direct-Acting Antivirals for Hepatitis C

Sanjay Kishore; Margaret Hayden; Micah Johnson; Aaron S. Kesselheim; Benjamin N. Rome

doi:10.1001/jama.2026.3328

March 25, 2026JAMA

National Prescribing Trends of Direct-Acting Antivirals for Hepatitis C

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to assess how prescriber and patient characteristics for hepatitis C treatment have evolved over time.
Analyzed prescribing data from 2013 to 2025 in the U.S.
Examined changes in patient demographics and prescriber habits.
Used statistical analysis to measure trends.
Identified significant changes in the demographics of patients receiving treatment.
Noted shifts in the characteristics and practices of prescribers over the years.
Detected trends that indicate evolving strategies in hepatitis C management.

Implication

Measures changes in prescribing patterns for hepatitis C treatment, implying shifts in treatment approaches in the U.S.

Abstract

This study measures changes in patient and prescriber characteristics for direct-acting antivirals to treat hepatitis C virus infection from 2013 to 2025 in the US.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kishore et al. (2026) studied this question.

synapsesocial.com/papers/69c6210b15a0a509bde1999a https://doi.org/10.1001/jama.2026.3328

View at Publisher

Ask AI

Bookmark

Share

National Prescribing Trends of Direct-Acting Antivirals for Hepatitis C

Key Points

Implication

Abstract

Discussion

Cite This Study

National Prescribing Trends of Direct-Acting Antivirals for Hepatitis C

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading